Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Endocrine resistance is a major challenge in breast cancer treatment.
• The Hippo pathway is implicated in tumor development and targeted therapies show promise, particularly in triple-negative breast cancer (TNBC).
• Dysregulation of the Hippo pathway is linked to various cancers and influences drug resistance.

Purpose of the Study:

• To explore the role of the Hippo pathway in endocrine resistance in breast cancer.
• To investigate the potential of targeting the Hippo pathway to enhance endocrine therapy efficacy.
• To review the mechanisms by which the Hippo pathway influences endocrine resistance.

Main Methods:

• Literature review and synthesis of existing research on the Hippo pathway and breast cancer.
• Analysis of the Hippo pathway's involvement in endocrine resistance mechanisms.
• Examination of studies combining Hippo pathway targeting with other therapies.

Main Results:

• The Hippo pathway is closely associated with endocrine resistance in breast cancer.
• It acts as a "co-correlation point" in multiple resistance pathways, including those involving breast cancer stem cells (BCSCs).
• Targeting Hippo pathway components or related microRNAs (miRNAs) may sensitize breast cancer cells to endocrine therapy.

Conclusions:

• The Hippo pathway presents a potential therapeutic target for overcoming endocrine resistance.
• Combining endocrine therapy with Hippo pathway-targeted agents is a promising strategy for endocrine-resistant breast cancers.
• Further research into Hippo pathway modulation could lead to improved breast cancer treatment outcomes.